This step requires typically 18 days but may vary between 2 and 4 weeks; (3) transfer of tumor cells to 24-well plates, to allow their adhesion to the plates overnight and addition of TIL at an E:T of 8:1 for 6–8 h; (4) magnetic bead separation with CD137 CliniMACS reagents and MACS ART columns, all CE approved; (5) standard rapid expansion of the CD137+ fraction with irradiated feeder cells, anti-CD3 antibody and IL-2, resulting in an approximately 1,000-fold expansion within 14 days; and (6) infusion. The gene discussed is TNFRSF9; the disease is neoplasm.